Tivic Health Completes Key Study for Nerve Stimulation Device, Anticipates Phase I Clinical Trial

Tivic Health (TIVC) has completed all study visits for its Optimization Study, which aims to determine the best parameters for its non-invasive device that stimulates the cervical vagus nerve. The study was conducted by The Feinstein Institute of Bioelectronic Medicine and the findings will be shared later this year. The study's insights will inform a forthcoming Phase I clinical trial to evaluate the device's effectiveness.

FREMONT, Calif.--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, has completed all study visits in its Optimization Study for a non-invasive cervical vagus nerve stimulation (ncVNS) device. Conducted by The Feinstein Institute of Bioelectronic Medicine, the study aimed to identify optimal device parameters such as frequency, amplitude, electrode positioning, and personalization, which are critical for influencing the autonomic nervous system function [1].

The study's initial findings highlight the significance of personalized treatment for therapeutic efficacy. Tivic Health expects to release the detailed study results later this year, which will inform its upcoming Phase I clinical trial [1]. The company's CEO, Jennifer Ernst, expressed confidence in their bioelectronic approach to developing vagus nerve stimulation therapies, noting that the findings could lead to differentiated treatments for numerous diseases [1].

The global vagus nerve stimulation (VNS) market is projected to grow from $8.59 billion in 2021 to $21.3 billion by 2030, representing a compound annual growth rate (CAGR) of 10.6% [2]. The segment of peripheral nerve stimulation, targeted by Tivic Health, is anticipated to grow at an even faster rate of 35% CAGR, supported by forecasts from IDTechEx [2].

Tivic Health's first FDA-approved product, ClearUP™, is designed to treat sinus pain and pressure and is available through online retailers and commercial distributors. The company continues to leverage its advanced bioelectronic technology platforms to develop personalized non-invasive medical devices aimed at modulating critical pathways in prevalent diseases [3].

References:
[1] https://www.businesswire.com/news/home/20250625233776/en/Tivic-Health-Completes-Optimization-Study-for-Its-Non-Invasive-Vagus-Nerve-Stimulation-Device
[2] https://www.gurufocus.com/news/2944937/tivic-health-completes-optimization-study-for-its-noninvasive-vagus-nerve-stimulation-device-tivc-stock-news
[3] https://www.biospace.com/press-releases/tivic-health-completes-optimization-study-for-its-non-invasive-vagus-nerve-stimulation-device